Teva Pharmaceutical Industries Ltd (TEVA) 53.22 $TEVA
Teva stops selling migraine patch after reports of burns
AP - Mon Jun 13, 11:25AM CDT
NEW YORK (AP) — Teva Pharmaceutical said Monday that it will stop selling its migraine patch treatment Zecuity after users reported burns and scars where it was applied. The company advised that anyone who has its patch should not use it.
TEVA: 53.22 (+0.21)
Teva Announces Voluntary Suspension of Marketing for ZECUITY(R) in the U.S.
BusinessWire - Mon Jun 13, 7:00AM CDT
Teva Pharmaceutical Industries, Ltd. (NYSE and TASE:TEVA) announced today that it will voluntarily suspend sales, marketing and distribution of ZECUITY(R) (sumatriptan iontophoretic transdermal system). Teva has received post-marketing reports of application site reactions described as burns and scars in patients treated with ZECUITY, and is working in full cooperation with the U. S. Food and Drug Administration (FDA) to better understand these adverse events. In addition to this voluntary suspension, Teva has initiated a pharmacy-level recall of the product.
TEVA: 53.22 (+0.21)
Teva Announces Favorable Court Ruling in TREANDA(R) (bendamustine hydrochloride) Patent Infringement Litigation
BusinessWire - Fri Jun 10, 1:20PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the United States District Court for the District of Delaware has ruled in favor of Teva in the Company's patent infringement lawsuit against Hetero USA, Inc., InnoPharma Inc., Hospira Inc., Sagent Pharmaceuticals Inc., and Accord Healthcare Inc., regarding Teva's TREANDA(R) (bendamustine hydrochloride) for Injection.
TEVA: 53.22 (+0.21)
Teva's Pain Drug Vantrela Recommended for FDA Approval
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 8:50AM CDT
Teva Pharmaceutical's (TEVA) Vantrela has been recommended for approval in the U.S.
PFE: 34.74 (-0.55), RTRX: 17.19 (-0.21), TEVA: 53.22 (+0.21), BMY: 72.22 (-0.43)
Teva Gains Recommendation for Approval from FDA Advisory Committees for VANTRELA(TM) ER (hydrocodone bitartrate) Extended-Release Tablets CII Formulated with Proprietary Abuse Deterrence Technology
BusinessWire - Tue Jun 07, 2:33PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 14 to 3 to recommend approval of VANTRELA(TM) ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. VANTRELA ER is an extended-release formulation of hydrocodone bitartrate with Teva's proprietary abuse deterrence technology.
TEVA: 53.22 (+0.21)
Teva to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Tue Jun 07, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Jefferies Healthcare Conference. Mike Derkacz will present on Thursday, June 9, 2016 at 1:30 PM ET.
TEVA: 53.22 (+0.21)
Teva to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Mon Jun 06, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Goldman Sachs 37th Annual Global Healthcare Conference. Siggi Olafsson will present on Wednesday, June 8, 2016 at 8:40 AM PT.
TEVA: 53.22 (+0.21)
Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected $4 Billion Market
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / Lupus - invisible, silent; an autoimmune disease where the body's defenses mistakenly attack its own cells and living with lupus is never ending. Up to 5 million people, mainly women of childbearing age, suffer progression of this disorder because of diagnostic confusion. Most present with fever, malaise and facial skin rash suggesting to internists other unrelated health problems. A capricious disease, lupus strikes in skin, joints, kidney, heart, pancreas, colon, eyes, blood...the list continues and flare-ups are sporadic. If organ damage is severe, lupus can be fatal.
XTLB: 1.08 (+0.05), TEVA: 53.22 (+0.21), GSK: 40.83 (-0.10)
Look for Shares of Teva Pharmaceutical Industries to Potentially Pullback after Yesterday's 1.56% Rise
Comtex SmarTrend(R) - Wed Jun 01, 12:54PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $51.67 to a high of $52.87. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $52.45 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 53.22 (+0.21)
After Yesterday's Rally of 1.56% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 01, 12:52PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $51.67 to a high of $52.87. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $52.45 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 53.22 (+0.21)
Teva's Huntington Disease Drug Receives CRL from the FDA
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:57AM CDT
Teva Pharmaceutical (TEVA) received a complete response letter from the FDA for SD-809 for the treatment of chorea associated with Huntington disease.
ANIP: 53.19 (+1.14), RTRX: 17.19 (-0.21), TEVA: 53.22 (+0.21), BMY: 72.22 (-0.43)
Teva to Present at the Bernstein 32nd Annual Strategic Decisions Conference
BusinessWire - Tue May 31, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Bernstein 32nd Annual Strategic Decisions Conference. Erez Vigodman will present on Friday, June 3, 2016 at 9:00 AM ET.
TEVA: 53.22 (+0.21)
Teva Receives Complete Response Letter for NDA for SD-809 for the Treatment of Chorea Associated with Huntington Disease
BusinessWire - Tue May 31, 6:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for SD-809 (deutetrabenazine) tablets for the treatment of chorea associated Huntington disease (HD). This is the first deuterated product to be reviewed by the FDA. The FDA has asked Teva to examine blood levels of certain metabolites. These metabolites are not novel, and are the same seen in subjects who take tetrabenazine or deutetrabenazine. No new clinical trials have been requested.
TEVA: 53.22 (+0.21)
Teva Achieves Positive Conclusion for the European Decentralised Procedure (DCP) for BRALTUS® (tiotropium bromide)
PR Newswire Europe - Mon May 30, 12:01PM CDT
AMSTERDAM, May 30, 2016 /PRNewswire/ --
TEVA: 53.22 (+0.21)
Teva Pharmaceutical Industries Rises 1.38% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed May 18, 1:00PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $51.38 to a high of $52.18. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $51.43 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 53.22 (+0.21)
AstraZeneca's Severe Asthma Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Wed May 18, 8:24AM CDT
AstraZeneca (AZN) announced positive data from two pivotal phase III studies on benralizumab for the treatment of severe asthma.
AZN: 27.60 (-0.37), TEVA: 53.22 (+0.21), GSK: 40.83 (-0.10), BMY: 72.22 (-0.43)
Look for Shares of Teva Pharmaceutical Industries to Potentially Rebound after Yesterday's 1.45% Sell Off
Comtex SmarTrend(R) - Thu May 12, 12:13PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $50.16 to a high of $51.60. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $50.84 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 53.22 (+0.21)
SmarTrend Watching for Potential Rebound in Shares of Teva Pharmaceutical Industries After 1.45% Loss
Comtex SmarTrend(R) - Thu May 12, 12:11PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $50.16 to a high of $51.60. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $50.84 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 53.22 (+0.21)
Teva to Present New Data at the 2016 American Thoracic Society (ATS) International Conference
BusinessWire - Thu May 12, 7:00AM CDT
Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that seven company-sponsored abstracts will be presented at the 2016 American Thoracic Society (ATS) International Conference in San Francisco, California on May 13-18, 2016.
TEVA: 53.22 (+0.21)
Teva stops selling migraine patch after reports of burns
AP - Mon Jun 13, 11:25AM CDT
NEW YORK (AP) — Teva Pharmaceutical said Monday that it will stop selling its migraine patch treatment Zecuity after users reported burns and scars where it was applied. The company advised that anyone who has its patch should not use it.
TEVA: 53.22 (+0.21)
Teva Announces Voluntary Suspension of Marketing for ZECUITY(R) in the U.S.
BusinessWire - Mon Jun 13, 7:00AM CDT
Teva Pharmaceutical Industries, Ltd. (NYSE and TASE:TEVA) announced today that it will voluntarily suspend sales, marketing and distribution of ZECUITY(R) (sumatriptan iontophoretic transdermal system). Teva has received post-marketing reports of application site reactions described as burns and scars in patients treated with ZECUITY, and is working in full cooperation with the U. S. Food and Drug Administration (FDA) to better understand these adverse events. In addition to this voluntary suspension, Teva has initiated a pharmacy-level recall of the product.
TEVA: 53.22 (+0.21)
Teva Announces Favorable Court Ruling in TREANDA(R) (bendamustine hydrochloride) Patent Infringement Litigation
BusinessWire - Fri Jun 10, 1:20PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the United States District Court for the District of Delaware has ruled in favor of Teva in the Company's patent infringement lawsuit against Hetero USA, Inc., InnoPharma Inc., Hospira Inc., Sagent Pharmaceuticals Inc., and Accord Healthcare Inc., regarding Teva's TREANDA(R) (bendamustine hydrochloride) for Injection.
TEVA: 53.22 (+0.21)
Teva's Pain Drug Vantrela Recommended for FDA Approval
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 8:50AM CDT
Teva Pharmaceutical's (TEVA) Vantrela has been recommended for approval in the U.S.
PFE: 34.74 (-0.55), RTRX: 17.19 (-0.21), TEVA: 53.22 (+0.21), BMY: 72.22 (-0.43)
Teva Gains Recommendation for Approval from FDA Advisory Committees for VANTRELA(TM) ER (hydrocodone bitartrate) Extended-Release Tablets CII Formulated with Proprietary Abuse Deterrence Technology
BusinessWire - Tue Jun 07, 2:33PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 14 to 3 to recommend approval of VANTRELA(TM) ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. VANTRELA ER is an extended-release formulation of hydrocodone bitartrate with Teva's proprietary abuse deterrence technology.
TEVA: 53.22 (+0.21)
Teva to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Tue Jun 07, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Jefferies Healthcare Conference. Mike Derkacz will present on Thursday, June 9, 2016 at 1:30 PM ET.
TEVA: 53.22 (+0.21)
Teva to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Mon Jun 06, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Goldman Sachs 37th Annual Global Healthcare Conference. Siggi Olafsson will present on Wednesday, June 8, 2016 at 8:40 AM PT.
TEVA: 53.22 (+0.21)
Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected $4 Billion Market
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / Lupus - invisible, silent; an autoimmune disease where the body's defenses mistakenly attack its own cells and living with lupus is never ending. Up to 5 million people, mainly women of childbearing age, suffer progression of this disorder because of diagnostic confusion. Most present with fever, malaise and facial skin rash suggesting to internists other unrelated health problems. A capricious disease, lupus strikes in skin, joints, kidney, heart, pancreas, colon, eyes, blood...the list continues and flare-ups are sporadic. If organ damage is severe, lupus can be fatal.
XTLB: 1.08 (+0.05), TEVA: 53.22 (+0.21), GSK: 40.83 (-0.10)
Look for Shares of Teva Pharmaceutical Industries to Potentially Pullback after Yesterday's 1.56% Rise
Comtex SmarTrend(R) - Wed Jun 01, 12:54PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $51.67 to a high of $52.87. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $52.45 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 53.22 (+0.21)
After Yesterday's Rally of 1.56% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 01, 12:52PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $51.67 to a high of $52.87. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $52.45 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 53.22 (+0.21)
Teva's Huntington Disease Drug Receives CRL from the FDA
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:57AM CDT
Teva Pharmaceutical (TEVA) received a complete response letter from the FDA for SD-809 for the treatment of chorea associated with Huntington disease.
ANIP: 53.19 (+1.14), RTRX: 17.19 (-0.21), TEVA: 53.22 (+0.21), BMY: 72.22 (-0.43)
Teva to Present at the Bernstein 32nd Annual Strategic Decisions Conference
BusinessWire - Tue May 31, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Bernstein 32nd Annual Strategic Decisions Conference. Erez Vigodman will present on Friday, June 3, 2016 at 9:00 AM ET.
TEVA: 53.22 (+0.21)
Teva Receives Complete Response Letter for NDA for SD-809 for the Treatment of Chorea Associated with Huntington Disease
BusinessWire - Tue May 31, 6:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for SD-809 (deutetrabenazine) tablets for the treatment of chorea associated Huntington disease (HD). This is the first deuterated product to be reviewed by the FDA. The FDA has asked Teva to examine blood levels of certain metabolites. These metabolites are not novel, and are the same seen in subjects who take tetrabenazine or deutetrabenazine. No new clinical trials have been requested.
TEVA: 53.22 (+0.21)
Teva Achieves Positive Conclusion for the European Decentralised Procedure (DCP) for BRALTUS® (tiotropium bromide)
PR Newswire Europe - Mon May 30, 12:01PM CDT
AMSTERDAM, May 30, 2016 /PRNewswire/ --
TEVA: 53.22 (+0.21)
Teva Pharmaceutical Industries Rises 1.38% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed May 18, 1:00PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $51.38 to a high of $52.18. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $51.43 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 53.22 (+0.21)
AstraZeneca's Severe Asthma Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Wed May 18, 8:24AM CDT
AstraZeneca (AZN) announced positive data from two pivotal phase III studies on benralizumab for the treatment of severe asthma.
AZN: 27.60 (-0.37), TEVA: 53.22 (+0.21), GSK: 40.83 (-0.10), BMY: 72.22 (-0.43)
Look for Shares of Teva Pharmaceutical Industries to Potentially Rebound after Yesterday's 1.45% Sell Off
Comtex SmarTrend(R) - Thu May 12, 12:13PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $50.16 to a high of $51.60. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $50.84 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 53.22 (+0.21)
SmarTrend Watching for Potential Rebound in Shares of Teva Pharmaceutical Industries After 1.45% Loss
Comtex SmarTrend(R) - Thu May 12, 12:11PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $50.16 to a high of $51.60. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $50.84 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 53.22 (+0.21)
Teva to Present New Data at the 2016 American Thoracic Society (ATS) International Conference
BusinessWire - Thu May 12, 7:00AM CDT
Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that seven company-sponsored abstracts will be presented at the 2016 American Thoracic Society (ATS) International Conference in San Francisco, California on May 13-18, 2016.
TEVA: 53.22 (+0.21)
